Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 13/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | AHCY | P23526 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3027373 | 0.89 | ADORA2A (0.57) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL3710259 | 0.86 | ADORA1 (0.55) | ADORA2AADORA3ADORA1CYP2D6ADORA2B | |
| SCHEMBL3022704 | 0.86 | ADORA1 (0.55) | ADORA2AADORA3ADORA1CYP2D6ADORA2B | |
| SCHEMBL3129561 | 0.79 | ADORA3 (0.50) | ADORA2AADORA3ADORA1 | |
| SCHEMBL3023215 | 0.79 | ADORA3 (0.50) | ADORA2AADORA3ADORA1 | |
| SCHEMBL590421 | 0.77 | ADORA2A (0.60) | ADORA2AADORA3AHCY | |
| SCHEMBL4367305 | 0.77 | ADORA2A (0.60) | ADORA2AADORA3AHCY | |
| SCHEMBL3022156 | 0.75 | ADORA2A (0.55) | ADORA2AADORA3ADORA1ADORA2B | |
| Trifluoroacetic Acid SCHEMBL588605 | 0.71 | ADORA2A (0.57) | ADORA2AADORA3ADORA1AHCY | |
| SCHEMBL3261712 | 0.69 | ADORA2A (0.66) | ADORA2AADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197914-A1 | Purine Derivatives as Adenosine Al Receptor Ligands | NOVARTIS AG (CH) | 2010-08-05 | — | — | US | disclosed |
| EP-2205601-A1 | PURINE DERIVATIVES AS ADENOSINE AL RECEPTOR LIGANDS | Novartis Ag (CH) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009050199-A1 | PURINE DERIVATIVES AS ADENOSINE AL RECEPTOR LIGANDS | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197914-A1 | Purine Derivatives as Adenosine Al Receptor Ligands | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA3 3/4885ADORA1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.